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an adverse effect on the muscle CSA SD score (OR 0.58 and 
0.46, respectively, p < 0.05).  Conclusion: There was a sexual 
difference with enlarged total and medullary CSA in females, 
whereas in males trabecular BMD was reduced and cortical 
BMD elevated. Cortical thickness and muscle CSA were re-
duced in all CAH patients with a possible long-term impact 
on bone development and stability. Monitoring of bone and 
muscle development might be warranted. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Congenital adrenal hyperplasia (CAH) is a group of 
autosomal recessive disorders resulting from deficiency 
of one of the five enzymes required for cortisol synthesis 
in the adrenal cortex. 21-Hydroxylase deficiency is the 
most frequent cause, accounting for more than 90% of all 
CAH cases. The majority of patients have a severe enzyme 
deficiency that results in the salt wasting (SW) form with 
insufficient aldosterone and cortisol biosynthesis. The re-
sult of a less severe deficiency is the simple virilizing (SV) 
form with insufficient production of cortisol. Patients 
with 21-hydroxylase deficiency require long-term gluco-
corticoid (GC) treatment. Most patients need the addi-
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 Abstract 
 Background/Aims: Glucocorticoid treatment may influence 
bone and muscle development in patients with congenital 
adrenal hyperplasia (CAH). This study evaluated bone min-
eral density (BMD), bone geometry and muscle mass.  Meth-
ods: 73 adult patients with classical CAH were followed. 
BMD, bone geometry and muscle mass were measured us-
ing peripheral quantitative computed tomography (pQCT). 
Glucocorticoid-equivalent doses throughout life were calcu-
lated and at the time pQCT androgen levels were measured. 
 Results: In males the mean standard deviation (SD) score for 
trabecular BMD (–0.33 ± 0.71) was reduced, whereas mean 
cortical BMD (1.05 ± 1.11) was elevated. Mean total (0.86 ± 
1.12) and medullary cross-sectional area (CSA; 1.12 ± 1.17) 
were significantly increased (p < 0.001). In all patients SD 
scores for cortical thickness (–0.65 ± 0.91) and muscle CSA 
(–0.83 ± 0.91) were reduced. Treatment duration was associ-
ated with lower trabecular BMD in males (r = –0.63, p < 
0.001). Suppressed androgens and simple virilizing CAH had 
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tion of mineralocorticoids. GCs both replace the deficient 
cortisol and reduce the overstimulation of the adrenal 
cortex  [1] . It is quite difficult to reduce excess androgen 
without giving higher GC doses  [2] . Finding the balance 
between too much and too little GC treatment is espe-
cially difficult because current available GCs do not allow 
to replicate the physiological circadian rhythm of cortisol 
secretion  [3] .
 Evidence exists regarding the potential impact of long-
term GC treatment on bone mineral density (BMD), 
bone geometry and muscle development in adults with 
CAH  [4] . Chronic GC therapy is a known risk factor for 
osteoporosis  [5] . On the other hand, androgens may be 
osteoprotective. The osteoblastic effect of androgens is 
thought to be mediated by estrogen receptors with stimu-
lation of bone formation  [6, 7] . In patients with CAH, 
published data are conflicting with BMD values being re-
ported as unchanged, elevated or reduced  [8–10] . A wide 
range of age at investigation, heterogeneous groups in-
cluding classical and non-classical forms, variable GC 
dose and form, and inclusion of pre- and postpubertal 
patients might explain in part the differences between 
studies  [8, 11, 12] .
 Most studies on BMD in CAH used dual-energy X-ray 
absorptiometry (DXA) measurements  [4] . However, 
since the densitometric data obtained by DXA are greatly 
influenced by bone size, the height and weight of the sub-
jects must be considered. This is an important issue as 
CAH patients have a final height at the lower limit of nor-
mal  [13] . Peripheral quantitative computed tomography 
(pQCT) images a cross-sectional view of the limb and 
provides volumetric, three-dimensional assessment of 
the structural (BMD) and geometric properties (bone 
size) of the appendicular skeleton – information which is 
not provided by DXA. A further advantage of pQCT is its 
ability to measure the muscle cross-sectional area (CSA) 
of the limb.
 The cohort consisted of adolescent and adult male and 
female patients with classical CAH. Our objective was to 
study the impact of chronic GC treatment on bone mass, 
density, geometry and the muscle-bone relation at the ra-
dius using pQCT.
 Subjects and Methods 
 We followed 73 patients (36 female) born between 1966 and 
1992 with 21-hydroxylase deficiency continuously from infancy 
until adulthood in our tertiary health care center (Division of En-
docrinology, University Children’s Hospital of Munich). The di-
agnosis of classical CAH was based on both clinical symptoms and 
signs and on hormonal analysis and was confirmed by subsequent 
comprehensive genotyping  [14] . At the time of diagnosis, newborn 
screening for CAH was not yet available. 41 (20 female) patients 
had SW CAH and 32 (16 female) had the SV form. Patients with 
additional diseases possibly affecting bone development were not 
included in this cross-sectional study (2 patients with seizure and 
anticonvulsive treatment). All patients had received hydrocorti-
sone (HC) three times daily for GC replacement during their 
growth period with the exception of 2 who were treated with pred-
nisone. Thereafter, some switched to longer-acting GCs [dexa-
methasone in 3 (1 female), prednisone in 28 (16 female)]. GC dos-
es were converted to cortisol equivalents using growth-retarding 
equivalents (80 mg HC = 16 mg prednisone = 1 mg dexametha-
sone)  [15] . Mean daily GC doses per square meter of body surface 
area were analyzed at start of puberty, at final height and in ado-
lescent/adulthood at the time of pQCT measurement. pQCT mea-
surement was performed between 2002 and 2010 in all adolescent 
and adult patients before transition to the adult clinic.
 Anthropometric data were compared with the cross-sectional 
growth data of Brandt and Reinken  [16] . The pQCT results were 
compared with data of adult participants of the Donald study or 
their parents of similar age range (15.0–9.9 years) measured with 
identical methodology  [17, 18] . Additionally, we used height-spe-
cific reference data from the same population.
 Height was measured in the standing position to the nearest
1 mm using a digital telescopic wall-mounted stadiometer (Ulmer 
Stadiometer; Prof. E. Heinze, Ulm, Germany). Weight was deter-
mined to the nearest 0.1 kg using an electronic scale (Seca 753 E; 
Vogel & Hanke, Hamburg, Germany) with the patients clothed in 
underwear. Forearm length was measured at the non-dominant 
forearm as the distance between the ulnar styloid process and the 
olecranon using a caliper. At start of puberty, defined by Tanner 
stage B2 in females and testicular volume >3 ml in males  [19] , bone 
age was determined on an X-ray of the left hand and wrist by the 
method of Greulich and Pyle  [20] .
 Peripheral Quantitative Computed Tomography 
 Two sites of the non-dominant radius were analyzed by pQCT 
(XCT 2000 Scanner; Stratec, Inc., Pforzheim, Germany), the distal 
metaphysis (‘4% site’) and the proximal diaphysis (‘65% site’) as 
described before  [17, 21] . The measurement was performed on the 
radius whose distance to the radial articular surface corresponded 
to 4 and 65% of forearm length. At both sites a 2-mm-thick single 
tomographic slice was sampled at a voxel size of 0.4 mm. Image 
processing and calculation of numerical values was done using the 
manufacturer’s version 5.40 software package (Stratec, Inc.).
 At the distal radius (metaphyseal site) trabecular BMD, at the 
proximal radius (diaphyseal site) cortical BMD, bone mineral con-
tent (BMC), total CSA, cortical CSA and cortical thickness were 
measured. Further, muscle CSA was calculated by the manufac-
turer’s software. 
 Endocrine and Metabolic Assessment 
 At the time of bone evaluation a routine blood analysis (blood 
cell count, electrolytes, and liver and renal function tests) was ob-
tained. Blood samples were taken in the morning in all subjects. 
17-Hydroxyprogesterone (17-OHP) was assayed by an enzyme 
immunoassay (IBL, Hamburg, Germany) and androstenedione 
and testosterone by commercial enzyme-labeled immunometric 
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ny). Dehydroepiandrosterone sulfate (DHEAS) was assayed by 
commercial electrochemiluminescence immunoassay (Elecsys 
2010; Roche Diagnostics, Mannheim, Germany) in our laboratory. 
Test sensitivities were 0.08 nmol/l for 17-OHP and androstenedi-
one, 0.02 nmol/l for testosterone, and 0.003 μmol/l for DHEAS. 
Intra- and interassay variations were 6 and 11.3% for 17-OHP, 8.1 
and 9.8% for androstenedione, 3.8 and 6.2% for testosterone, and 
3.5 and 4.6% for DHEAS.
 Statistical Analysis 
 Anthropometric measurements of CAH patients were convert-
ed into sex-, age- and height-specific standard deviation (SD) 
scores using the formula: SD score = [(test result for a patient) – 
(age- or height-specific mean in reference population)]/(age- or 
height-specific SD in reference population). Results are presented 
as mean ± SD. Differences from an age-matched healthy popula-
tion were tested by one-sample t test of the mean SD score against 
zero. For between-group comparisons (SW vs. SV, female vs. 
male) we used Student’s t test and in case of non-normally distrib-
uted variables the non-parametric Mann-Whitney U test. Correla-
tions between variables were determined by Pearson’s method.
 We performed a linear regression analysis to evaluate the as-
sociations between different bone parameters such as trabecular 
BMD, cortical BMD, total bone CSA, cortical thickness and muscle 
CSA (SD scores) (separate dependent variables) and body mass 
index (BMI), final height SD score, HC-equivalent dose per square 
meter body surface area (at start of puberty, at final height and at 
present), and the binary variables diagnosis (SW = 0 vs. SV = 1) 
and suppressed adrenal androgens (suppressed = 0 vs. not sup-
pressed = 1) (predictors), additionally adjusted for sex and age. 
Backward variable selection was also applied based on the Akaike 
Information Criterion  [22] .
 Throughout the level of significance for each test was set to 
0.05. Calculations were performed using the statistical package 
SPSS for Windows (version 14.0; SPSS, Inc., Chicago, Ill., USA) 
and R-2.12 (http://cran.r-project.org). The study protocol was ap-
proved by the Ethics Committee of Ludwig Maximilians Univer-
sity, Munich, and by the Federal Office for Radiation Protection. 
Informed consent was obtained from all patients and/or their par-
ents.
 Results 
 Auxological Data and Medication 
 Patients with SW CAH were diagnosed early at a mean 
age of 0.07 ± 0.19 years (range 0.0–0.5, median 0) , where-
as patients with the SV form were diagnosed at a mean 
age of 1.96 ± 1.95 years (range 0.0–6.0, median 1.5) . None 
of the patients had suffered from adrenal crisis once SW 
CAH was diagnosed.  Table 1 summarizes the auxological 
data of the study population divided by sex and type of 
CAH.
 Females with SV CAH were significantly older than 
females with SW CAH (p = 0.004). Mean final height was 
159.9 ± 6.5 cm (–0.85 ± 1.14 SDS) in females, those with 
SW being significantly taller (p = 0.017). Mean final 
height in males was 170.1 ± 6.8 cm (–1.08 ± 0.99). There 
was no significant height difference between male SW 
and SV. BMI SD score was significantly higher than in the 
 Table 1.  Auxology, medication and serological data in adult CAH patients divided by sex and subtype
Parameters Females (n = 36)  Males (n = 37)
SW (n = 20) SV (n = 16) S W (n = 21) SV (n = 16)
Age at investigation, years   20.7 (16.7 – 36.4)   30.4 (16.2 – 43.7)a    21.3 (17.8 – 43.0)    21.1 (17.1 – 42.5) 
Age at diagnosis, years    0.19 ± 0.09   1.03 ± 1.66a    0.38 ± 1.15   2.74 ± 1.81a
Final height, cm      161.70 ± 4.86    157.50 ± 7.54a      170.20 ± 6.96    170.0 ± 6.67
Final height SD score   – 0.45 ± 0.84b  – 1.35 ± 1.29a   – 1.04 ± 1.03b  – 1.13 ± 0.94
BA advanced at puberty start, years    0.09 ± 0.3    0.55± 0.52a    0.50 ± 0.52b   0.55 ± 0.53a
Age at menarche, years     13.82 ± 1.64    13.79 ± 2.11 – –
HC-E dose at puberty start     15.19 ± 3.61    19.39 ± 5.32a     19.48 ± 8.06    20.18 ± 4.53
HC-E at FH     16.75 ± 4.25    19.84 ± 4.19     19.29 ± 4.04    18.98 ± 2.71
HC-E at present     17.43 ± 5.10    18.00 ± 4.46     19.52 ± 4.99    19.58 ± 4.23
BMI SD score    0.79 ± 1.08b   0.76 ± 1.87b    0.72 ± 1.27b   0.25 ± 1.14
17-OHP, nmol/l   6.6 (1.21 – 297)   7.3 (0.42 – 248)   7.6 (1.45 – 226)    10.12 (1.91 – 227)
Androstenedione, nmol/l    1.86 (0.66 – 73.5)   1.96 (0.52 – 73.5)   2.94 (1.26 – 27.6)   2.83 (1.05 – 178.2)
DHEAS, μmol/l    0.20 (0.14 – 2.70)   0.25 (0.14 – 2.29)    1.01 (0.14 – 11.91)   1.48 (0.46 – 13.27)
Testosterone, nmol/l    1.93 (0.40 – 13.19)   0.93 (0.52 – 3.12)    14.26 (5.55 – 31.82)    13.10 (2.14 – 25.33)
 Data are shown as mean ± SD or median (range) as indicated. BA = Bone age. a Significant difference between SV and SW CAH (for 
males and females; Student’s t test or Mann-Whitney U test, if appropriate). b Significant difference compared to a healthy reference 
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reference population in all patients apart from males with 
SV CAH. Bone age at start of puberty was comparable in 
male (both groups) and female SV with about +0.5 years 
advanced. However, bone age was almost identical with 
chronological age in female SW. In addition, all patients 
had entered and completed puberty at a normal age range. 
Females had regular menses with 4 of them being on con-
traceptives, and boys had a mean testicular volume of 18 
± 2.3 ml with normal adult plasma testosterone values.
 Biochemical Evaluation 
 Considering the whole group of CAH patients, the un-
derlying disease was well controlled in the majority of pa-
tients, as indicated by the slightly advanced bone age at 
start of puberty, final height and laboratory parameters. 
DHEAS concentrations were consistently below normal 
for age, androstenedione levels mostly within the normal 
range, whereas 17-OHP levels were significantly elevated 
in comparison to the reference data but within the ac-
cepted range of up to 30 nmol/l in the majority of patients. 
In a subgroup analysis, 17 patients seem to be overtreated 
with a combination of suppressed DHEAS levels ( ≤ 0.14 
μmol/l), 17-OHP levels <5.4 nmol/l as well as low andro-
stenedione values <3.5 nmol/l. In 15 patients, 17-OHP 
levels were >30 nmol/l combined with elevated androgen 
levels possibly due to a too low dose or a lack of compli-
ance.
 BMD and Bone Geometry Results 
 In male CAH patients there was a significant reduction 
in trabecular BMD SD score (–0.33 ± 0.71), whereas cor-
tical BMD SD score (1.05 ± 1.11) was elevated. Total CSA 
SD score was normal (–0.10 ± 0.93) and medullary cavity 
SD score was slightly elevated (0.21 ± 0.71, p = 0.081), 
therefore SD scores of cortical CSA (–0.49 ± 1.17) and 
cortical thickness (–0.54 ± 0.88) were significantly re-
duced (p = 0.016 and 0.001, respectively) ( fig. 1 ). Muscle 
CSA SD score (–0.87 ± 0.78) was reduced (p < 0.001), also 
after adjustment for height (–0.64 ± 0.43, p < 0.05). There 
was a difference in muscle CSA between male subtype of 
CAH with significantly higher values in SV (p = 0.05;  ta-
ble 2 ).
 In female patients, BMD parameters (trabecular, corti-
cal) were within the normal range, total (0.86 ± 1.12) and 
medullary CSA SD score (1.12 ± 1.17) were significantly 
Cortical thickness
Healthy adult Male with CAH Female with CAH
Total bone CSA
Cortical CSA and density Medullary cavity
 Fig. 1. Schematic, cross-sectional view of the appendicular skele-
ton in male and female CAH adults: the result of an enlarged med-
ullary cavity is a smaller cortical thickness. In females, total CSA 
of the bone is larger in relation to a healthy reference population 
(left side). In males, cortical BMD is elevated indicated by a re-
duced number of points within the cortex (less porosity). 
 Table 2.  BMD and bone geometry parameters in adult CAH patients divided by sex and subtype
Parameters (SD scores) Females (n =  36)  Males (n = 37)
SW (n = 20) SV (n = 16) SW (n = 21) SV (n = 16)
Trabecular BMD –0.24 ± 0.74 –0.09 ± 0.94 –0.35 ± 0.74a –0.32 ± 0.67a
Cortical BMD 0.18 ± 1.13 0.07 ± 1.18 1.12 ± 1.17a 0.95 ± 1.05a
Total CSA 0.94 ± 1.36a 0.75 ± 1.07a –0.21 ± 0.91 0.05 ± 0.98
Medullary CSA 1.12 ± 1.17a 1.11 ± 1.21a 0.06 ± 0.71 0.40 ± 0.68a
Cortical CSA 0.16 ± 1.17 –0.30 ± 1.19 –0.46 ± 1.22 –0.53 ± 1.14
Cortical thickness –0.64 ± 0.82a –0.93 ± 1.08a –0.45 ± 0.96a –0.65 ± 0.77a
BMC 0.03 ± 1.32 –0.31 ± 1.22 –0.49 ± 1.18 –0.62 ± 1.30
Muscle CSA –0.82 ± 1.02a –0.76 ± 1.08a –1.09 ± 0.86a –0.58 ± 0.56a,b
 Data are shown as mean ± SD. a Significant difference between CAH patients and a healthy reference popu-
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larger (<0.001) than in the reference population, with the 
consequence of a reduced cortical thickness (–0.77 ± 0.94, 
p < 0.001) ( fig. 1 ). As in male patients the muscle CSA SD 
score was reduced (–0.79 ± 1.03, p < 0.001). 
 Relationship between BMD/Bone Geometry and
Other Parameters 
 In the whole patient population no significant influ-
ence on bone parameters by present HC-equivalent dose, 
dose at onset of puberty or at the age near final height was 
detectable. When we built groups using a cut-off level for 
HC-equivalent dose at the different time points (onset of 
puberty, at final height and at present) of 17 mg/m 2 , as 
recommended in the literature  [2] , again no significant 
differences were detectable. 23 patients were overweight 
and had a BMI above the 90th percentile. No significant 
difference with regard to bone parameters between nor-
mal and overweight patients was observed. The BMI cor-
related with the muscle mass in all (r = 0.38 for males and 
r = 0.55 for females, p < 0.02), leading to a trend for a 
higher muscle mass with increasing BMI. Treatment du-
ration and age at evaluation might play a role. In males, 
duration of GC treatment was negatively associated with 
trabecular BMD (r = –0.63, p < 0.001) and BMC (r = 
–0.33, p = 0.048), while no association was found in fe-
males ( fig. 2 ).
 Some of our patients were considered to be overtreat-
ed with androgen levels almost suppressed. Performing a 
comparison between overtreated (n = 17), normal treated 
(n = 43) and undertreated or less compliant (n = 15) pa-
tients, those with overtreatment had the smallest muscle 
CSA (–1.30 ± 0.69 vs. –0.52 ± 0.66 for undertreated, p < 
0.001). Patients with serological signs of undertreatment 
were more prone to be treated by HC (74%), whereas in 
normal or overtreated CAH patients, 40 and 50%, respec-
tively, were on long-acting GC (prednisone or dexameth-
asone). 
 In multiple regression models ( table  3 ) adjusted for 
age and sex, HC-equivalent dose per square meter at final 
height was positively associated with trabecular BMD SD 
score (β = 0.07; 95% CI 0.00, 0.13) but negatively with 
cortical thickness (β = –0.07; 95% CI –0.13, –0.01) after 
backward selection. The present HC-equivalent dose did 
not show a significant influence on bone density or geom-
etry (data not shown). Lower muscle CSA SD score was 
associated negatively with the diagnosis of SV (β = –0.46; 
95% CI –0.81, –0.11), but positively with BMI (β = 0.13; 
95% CI 0.09, 0.17) and suppressed androgens (β = 0.57; 
95% CI 0.12, 1.03). There were no significant associations 
between cortical BMD and total CSA and any of the pre-
dictors (data not shown).
 Discussion 
 To the best of our knowledge this is the first study us-
ing pQCT for the evaluation of bone density and geom-
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 Fig. 2. Relation of GC treatment duration with trabecular BMD SD scores in patients with CAH: upper panel 
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of this study were reduced cortical thickness and muscle 
CSA in all patients. In females bone geometry was altered 
with enlarged total and medullary CSA, whereas in males 
trabecular BMD was reduced and cortical BMD elevated.
 There are a number of studies in the literature that as-
sessed BMD in individuals with CAH with a wide spec-
trum of results. DXA was the technique mostly used. 
However, caution is necessary with this technique since it 
is dependent on bone and body size. CAH adults have a 
reduced final height and therefore underestimated BMD 
data might be the consequence of DXA measurement. 
We therefore used the pQCT method which gives data on 
real volumetric BMD and bone geometry.
 In this population, trabecular BMD appeared to be 
maintained in female but not in male CAH patients. This 
is in accordance with previous reports on lower BMD val-
ues in males  [11, 23] . Further, in male CAH patients cor-
tical BMD was significantly elevated. The reduction in 
trabecular and elevation in cortical BMD could be the 
consequence of long-term GC treatment characterized by 
lower bone turnover  [24] . Women with CAH might ben-
efit from the preserving effect of estrogens combined with 
the additive effect of androgens  [25] . In males the elevat-
ed adrenal androgens may suppress the hypothalamic-
gonadal axis with the result of smaller testes and lower 
testosterone, thereby influencing bone development  [26] .
 The BMI of CAH patients was significantly higher as 
in most previous studies  [13, 23, 27] . BMI also appeared 
to protect patients with CAH from bone loss. Chakhtou-
ra et al.  [23] could show that a higher BMI was associated 
with a higher bone density in adult patients with CAH. In 
this study an increase in BMI by 1 point was associated 
with an increase in muscle mass by 0.13 SD. BMI had no 
influence on BMD or bone geometry parameters. How-
ever, looking at patients below the age of 30 years, there 
was a significant correlation between BMI and total CSA 
(r = 0.32) and medullary CSA (r = 0.31).
 There seems to be a difference in results with regard to 
which age group was chosen in the different studies. Dis-
ease duration or age is known to be an important con-
founding factor  [28, 29] . In previous studies with a young-
er patient population (<30 years of age) normal values of 
trabecular BMD at the spine were described  [9, 28, 30, 
31] . With increase in age of the population (>30 years of 
age) lower BMD levels were found  [4, 8, 22] . One expla-
nation for this relation might be the cumulative lifelong 
GC dose  [12, 31, 32] . A second explanation might be the 
higher GC dosing used in infancy in those of older age. 
Further, in young adults the negative effect of GC on bone 
could be balanced by the positive effects of androgens  [28, 
33] . In this study with longer disease duration and there-
fore higher cumulative GC dose, patients had a lower tra-
becular BMD and a lower bone mass. In patients with 
Addison disease, low BMD was found especially in males 
with low testosterone and in postmenopausal women 
 [34] . This scenario may also apply for older CAH pa-
tients.
 Cortical thickness was reduced in males and females 
possibly as a result of increased endosteal bone resorption 
as a consequence of GC treatment  [5] . GC dosing at a 
single time point as at final height had only a mild influ-
ence, e.g. with each increase in HC-equivalent dose at fi-
nal height of 1 mg/m 2 a decrease of cortical thickness SD 
score by 0.07 was associated.
 Total and medullary CSA were significantly elevated 
in female CAH patients, but not in males (apart from a 
significant elevation of medullary cavity in male SV). In 
females, bone geometry might be altered in favor of peri-
osteal bone apposition. This could be explained by early 
influences of androgens on bone development. Andro-
gens enhance osteoblast differentiation and influence os-
teoclast activity. In both sexes androgens may stimulate 
periosteal apposition  [35] . In males with lower levels of 
estrogens, periosteal apposition might be upregulated, 















BMI 0.02 (–0.03, 0.06) 0.01 (–0.06, 0.07) –0.04 (–0.02, 0.11) 0.05 (–0.01, 0.10) 0.13 (0.08, 0.17) 0.13 (0.09, 0.17)
HCE puberty –0.01 (–0.05, 0.03) –0.01 (–0.07, 0.05) –0.01 (–0.07, 0.05) 0.02 (–0.03, 0.07) 0.04 (0.00, 0.07)
HCE at FH 0.07 (0.00, 0.13) 0.06 (–0.04, 0.16) 0.02 (–0.08, 0.12) 0.07 (–0.15, 0.01) –0.07 (–0.13, –0.01) –0.05 (–0.12, 0.01)
Diagnosis –0.21 (–0.59, 0.17) –0.07 (–0.63, 0.5) –0.04 (–0.60, 0.52 0.09 (–0.35, 0.54) –0.46 (–0.81, –0.11) –0.48 (–0.84, –0.12)
Suppression 0.24 (–0.26, 0.74) –0.63 (–1.37, 0.12) 0.13 (–0.61, 0.87) 0.38 (–0.21, 0.97) 0.57 (0.11, 1.04)
 Values are presented as β (95% CI). Bold values determine significant associations. β = Regression coefficient; FH = final height (expressed as SD score according to Brandt and 
Reinken [16]); HCE puberty = HC-equivalent dose per square meter at onset of puberty; HCE at FH = HC-equivalent dose per square meter at final height; Diagnosis = SW CAH clas-
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whereas in females endogenous estrogens may inhibit 
periosteal apposition through interaction with IGF-1 
 [36] . Recent evidence suggests that the higher IGF-1 lev-
els in males may depend on neonatal androgen action 
 [37] . In females with CAH and elevated androgens from 
early on in life, it is suggestive that androgens are respon-
sible for an elevated total and medullary CSA. 
 Androgens additionally increase muscle mass and 
strength  [7] . Surprisingly, muscle mass was low in all CAH 
patients, especially in SV CAH. This may have long-term 
consequences on bone development since the largest bone 
loads come from muscle force. Consequently, chronically 
reduced muscle forces result in a disuse osteopenia. 
 There was no significant association between BMD, 
bone geometry and 17-OHP or androstenedione and also 
no influence of present HC-equivalent dose. However, 
overtreated patients had the lowest muscle mass, indicat-
ing treatment induced sarcopenia. Previous studies could 
demonstrate the effect of GC overdosing only on BMD in 
adult CAH  [12] . Future studies have to evaluate if a lower 
dose in infancy and during pubertal years has an impact 
on muscle and bone development. In general, overtreat-
ment with GC has to be avoided.
 An advantage of our study is a regular follow-up of 
adolescent and adult patients with classical CAH in a sin-
gle outpatient clinic treated similarly. Appropriateness of 
their GC dose was checked based on their steroid serum 
and urine concentration, growth and development. A 
weakness is its cross-sectional design and a relatively 
small sample resulting in small numbers in the four sub-
groups and a heterogeneous age distribution. No data on 
physical activity and diet were collected. Further, espe-
cially older patients were treated with higher doses in in-
fancy and throughout childhood that might have had an 
influence on bone development. Serological and mor-
phological measures recorded represent only one win-
dow in time. Patient’s compliance and response to medi-
cation may greatly vary over time.
 To conclude, the population at particular risk might be 
male patients with a long GC treatment duration, a lower 
BMI, low muscle mass and suppressed androgens. In fe-
males, estrogens and androgens may have an additive ef-
fect on bone development leading to bone expansion, at 
least in the younger age group. We may suppose that with 
age CAH patients develop lower BMD. Physicians should 
bear in mind the potential consequences of GC on bone 
by adjusting the treatment and improve clinical and labo-
ratory surveillance from infancy on  [23] . It is important 
to use the lowest possible GC dose. Lifelong proficient 
medical care for CAH patients should be assured. Follow-
up BMD measurements in adults are justified, even if a 
normal BMD is found in early adulthood  [29] .
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